ADC Therapeutics S.A. (ADCT) Fundamental Analysis: Bull vs. Bear Case

ADCT

ADC Therapeutics S.A.

Fundamental data last updated:May 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NYSE

County of HQ

CH

Next Earnings Date

08/11/2026

Business Summary

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

VALUATION

P/E

-3.92

Market Cap ($M USD)

$442.62M

Forward P/E

4.15 PEG

0.02 PRICE TO SALES

5.59 PRICE TO BOOK

-2.48

EV / EBITDA

-7.21

5-Year Average P/E

Free Cash Flow Yield

-25.89%

DCF Value

$-10.74

Graham Number

N/A

Price to FCF

-3.86

EV to FCF

-5.52

Earnings Yield

-25.54%

FCF Yield

-25.89%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.89

Next Year EPS Growth Estimate

$0.84

Next Year Revenue Growth Estimate

$46.24B

Return on Equity (ROE)

65.27%

FREE CASH FLOW

Operating Margin

-149.65%

Debt-to-Equity

-2.36

Piotroski F-Score

3 Altman Z-Score

-7.33

Return on Invested Capital (ROIC)

-52.93%

Current Ratio

4.09 Quick Ratio

4.02 Net Debt to EBITDA

-2.17

Interest Coverage

-2.29

Gross Profit margin

90.71%

FCF PER SHARE

$-0.74

REVENUE PER SHARE

$0.51

Gainseekers Quantitative Analysis

Summary

ADCT’s valuation paints a complex picture. The market has priced it significantly below its DCF value, suggesting potential mispricing. However, a Forward P/E of 4.18 indicates some optimism about future earnings, contrasting sharply with a negative Earnings Yield and a troubling Altman Z-score of -7.36, which signals financial distress. The negative Price/Book ratio further underscores potential balance sheet issues. Despite these concerns, the stock’s current pricing reflects a cautious market stance, wary of its financial health.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, ADCT is inherently positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid tech evolution could enhance its R&D efficiency. However, the company's current financial instability may hinder its ability to capitalize on these opportunities fully.

The Bull Case

For the discerning GARP investor, ADCT offers intriguing prospects. The company's Return on Equity of 65.27% suggests robust capital efficiency, while a Piotroski F-Score of 3 indicates some financial strength amidst challenges. Despite a negative FCF Yield, the potential for significant sales growth next year could translate into improved cash flows. These factors hint at a company with latent pricing power, poised for a turnaround if management can harness its operational strengths.

The Bear Case

Yet, the bear case is compelling. ADCT's structural weaknesses are glaring, with an Operating Margin of -149.65% and a negative ROIC of -52.93%, highlighting severe profitability issues. The negative EV to EBITDA and Price to FCF ratios further emphasize its cash flow struggles. Additionally, trading near its 52-week high, the stock appears technically overextended, raising concerns about its current valuation sustainability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$7.50

Institutional Ownership %

1-Year Beta

1.84 Insider Buying % (6 Mo)

Distance to 52-Week High

43.10%

Distance to 52-Week Low

63.97%

EARNINGS SURPRISE %

-10.53%

50-DAY SMA

$3.98

200-DAY SMA

$3.79

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.